KEGG   DRUG: Xanomeline and trospium chloride
Entry
D12968            Mixture   Drug                                   
Name
Xanomeline and trospium chloride;
Cobenfy (TN)
Product
COBENFY (E.R. Squibb & Sons)
Component
Xanomeline tartrate [DR:D06331], Trospium chloride [DR:D01103]
Class
Metabolizing enzyme substrate
 DG01644  CYP2D6 substrate
Remark
Product: D12968<US>
Efficacy
Antipsychotic
  Disease
Schizophrenia [DS:H01649]
Comment
CYP2D6 contributes significantly to the metabolism of xanomeline, a component of COBENFY.
Metabolism
Enzyme: CYP2D6 [HSA:1565]
Interaction
Brite
USP drug classification [BR:br08302]
 Antipsychotics
  Antipsychotics, Other
   Xanomeline/ Trospium
    D12968  Xanomeline and trospium chloride
Drug groups [BR:br08330]
 Metabolizing enzyme substrate
  DG01644  CYP2D6 substrate
   D12968  Xanomeline and trospium chloride
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12968
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12968
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D12968
Other DBs
PubChem: 503268988
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system